CD274 and non-small cell lung carcinoma: demonstrated that a radiographic image-based biomarker on baseline CT scans is significantly associated with progression-free survival and overall survival (specifically prognostic within individual PD-L1 categories) in patients with NSCLC treated with durvalumab (anti PD-L1 monoclonal antibody) after chemoradiotherapy (CRT) or CRT alone by using radiomic texture patterns within and outside the NSCLC tumor cells (63).